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ABSTRACT
The heritability of classical Hodgkin lymphoma (cHL) has yet to be fully 
deciphered. We report a family with five members diagnosed with nodular sclerosis 
cHL. Genetic analysis of the family provided evidence of linkage at chromosomes 
2q35-37, 3p14-22 and 21q22, with logarithm of odds score >2. We excluded the 
possibility of common genetic variation influencing cHL risk at regions of linkage, 
by analysing GWAS data from 2,201 cHL cases and 12,460 controls. Whole exome 
sequencing of affected family members identified the shared missense mutations 
p.(Arg76Gln) in FAM107A and p.(Thr220Ala) in SLC26A6 at 3p21 as being predicted 
to impact on protein function. FAM107A expression was shown to be low or absent in 
lymphoblastoid cell lines and SLC26A6 expression lower in lymphoblastoid cell lines 
derived from p.(Thr220Ala) mutation carriers. Expression of FAM107A and SLC26A6 
was low or absent in Hodgkin Reed-Sternberg (HRS) cell lines and in HRS cells in 
Hodgkin lymphoma tissue. No sequence variants were detected in KLHDC8B, a gene 
previously suggested as a cause of familial cHL linked to 3p21. Our findings provide 
evidence for candidate gene susceptibility to familial cHL.
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INTRODUCTION
Classical Hodgkin lymphoma (cHL) is the 
commonest lymphoid malignancy of young adults [1]. 
While cHL results from the neoplastic transformation of 
germinal centre B-cells, the characteristic Hodgkin and 
Reed-Sternberg (HRS) cells are typically seen at very low 
levels (1–10%), with most of the tumour consisting of a 
pleomorphic infiltrate but predominantly T-lymphocytes 
[2–4].
Epstein-Barr virus (EBV) infection is causally 
related to a number of cases [3, 5], but there is 
little evidence to support the involvement of other 
environmental or lifestyle risk factors. A role for inherited 
susceptibility to cHL is provided by familial risk 
[6, 7], including a high concordance in monozygotic 
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twins [8]. Although a strong human leukocyte antigen 
(HLA) association for cHL risk is established [9–14], 
this only accounts for <30% of the familial risk [15]. 
Direct evidence for the role of non-HLA genetics in cHL 
has come from recent genome-wide association studies 
(GWAS), which have identified common variants at 13 
loci associated with the risk of sporadic cHL [9, 14, 16, 
17]. In addition to common genetic variation influencing 
cHL, reports of familial aggregation raise the possibility 
of the existence of Mendelian susceptibility to the disease, 
caused by the inheritance of high-impact mutations [18]. 
A number of these multiple-case families have been the 
subject of linkage searches and various putative linkage 
signals reported; notably at 3p21.31 implicating germline 
variation in the kelch protein gene KLHDC8B [19]. 
Nodular sclerosis Hodgkin lymphoma (NSHL), the 
most common histological subtype of cHL in developed 
countries, is more frequent in young adults and women 
[4]. With the aim of furthering our understanding of cHL 
susceptibility, we describe a family in which five members 
have been diagnosed with the cHL subtype, NSHL. 
Seeking to identify a major risk locus responsible for cHL 
in the family, we conducted a genome-wide linkage scan 
and whole exome sequencing (WES) of affected family 
members. To complement the analysis, we also searched 
for evidence of association at regions of linkage by 
analysing a large GWAS dataset.
RESULTS
Linkage and mutation analysis
No region of the genome showed evidence 
for linkage with cHL in the family at genome-wide 
significance (i.e. logarithm of odds (LOD) score >3.0). 
Three regions of the genome, however showed evidence 
of linkage with a LOD score greater than 2.0: 2q35-37 
(220-237Mb), 3p14-22 (42-66Mb), 21q22 (42-47Mb) 
(Supplementary Figure 1). Linkage at 6p21 (HLA) was 
lacking and no shared HLA class I allele was shown 
between affected family members (Table 1). Previous 
studies have demonstrated a strong association between 
HLA class II alleles with EBV-negative NSHL. Only the 
HLA-DPB1*04:01 allele (Table 1), which has population 
frequency (>40%), was shared between affected family 
members. 712 coding variants were shared by affected 
family members (III-a, IV-b, IV-f and IV-g). Of these 712, 
only 37 mapped to the three regions of linkage. Restricting 
our analysis to those variants with a population frequency 
<1% and those predicted to impact on the protein function 
by both SIFT [20] and POLYPHEN-2 [21] algorithms, we 
identified p.(Arg76Gln) in FAM107A and p.(Thr220Ala) 
in SLC26A6 mapping to 3p21 as two plausible candidate 
variants causal for cHL in the family. We confirmed the 
fidelity of WES for both variants by Sanger sequencing. 
Finally, we did not identify any rare sequence variants in 
the previously identified candidate cHL susceptibility gene 
in this region, KLHDC8B, in any of the affected family 
members. 
Analyses of candidate genes
SLC26A6 expression was lower in lymphoblastoid 
cell lines from family members carrying the T220A 
mutation compared to unrelated healthy individuals 
(Figure 1). FAM107A expression was undetectable in 
lymphoblastoid cell lines. Expression of FAM107A and 
SLC26A6 was low or absent in HRS cell lines (Figure 2) 
and in HRS cells in Hodgkin lymphoma (Figure 3). 
Finally, expression levels of KLHDC8B were similar 
between lymphoblastoid cell lines from mutation carriers 
and non-carriers as well as between HRS cell lines and 
other cell lines (Figures 1 and 2). 
Association analysis of 2q35-37, 3p14-22, 21q22
To explore the possibility that variants with 
frequency greater than 1% might contribute to a 
relationship between 2q35-37, 3p14-22, 21q22 and 
cHL risk, we analysed directly typed and imputed 
genotypes in our large case-control series. Across 
the three regions we examined the relationship for 
107,472 SNPs and cHL risk (Supplementary Figure 
2). The strongest associations at 2q35-37, 3p14-22, 
21q22 were provided by rs6714255 (P = 5.79 × 10–6), 
rs115918946 (P = 1.70 × 10–4) and rs2839384 (P = 1.31 
× 10–3), which, after adjustment for multiple testing, 
were not statistically significant (i.e. P < 4.65 × 10–7,
0.05/107,472). Furthermore, these common genetic 
variants were not in linkage disequilibrium with the 
candidate genetic mutations in FAM107A and SLC26A6.
DISCUSSION
It is notable that we identified the class II HLA 
allele (DPB1*0401) as being shared between affected 
individuals. Although a HLA class II association is 
well established for NSHL, there is limited evidence 
to implicate this specific HLA allele. Excluding the 
possibility of multiplicative interaction with a non-
HLA linked allele, the pattern of inheritance of cHL in 
the family we describe is parsimonious with autosomal 
inheritance with incomplete penetrance. Predicated on this 
assumption, we sought to identify a disease locus for cHL 
in the family by performing a linkage scan. Although not 
statistically significant per se, we found suggestive linkage 
at 3p21, a region previously implicated by Salipante et al. 
[19], which in a combined analysis would provide a LOD 
score of >3.0. 
By performing WES of affected individuals we 
identified two rare protein-disrupting mutations in 
SLC26A6 and FAM107A on chromosome 3p21, as possible 
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Table 1: Clinico-pathological details of affected family members 
ID Stage Treatment Age at 
diagnosis
HLA type Subtype, EBV 
status
IV-f 2A 6 × ABVD 22 A*02:01,A*02:01, 
B*07:02,B*13:02, C*06:02,C*07:02, 
DRB1*07:01,DRB1*15:01, DRB4*01, 
DRB5*01, DQB1*02:02,DQB1*06:02, 
DPB1*04:01:01,DPB1*04:02
NSHL, LMP1 
negative.
IV-b 2A 6 × ABVD, 
radiotherapy
18 A*01:01,A*02:01, B*08:01,B*44:02, 
C*05:01,C*07:01, DRB1*01:01,DRB1*03:01, 
DRB3*01, DQB1*05:01,DQB1*02:01, 
DPB1*04:01:01
NSHL, 
unknown
III-g 2A 3 × ABVD, 
radiotherapy
31 A*03:01, B*07:02,B*49:01, C*07:01,C*07:02, 
DRB1*04:01,DRB1*15:01, DRB4*01, 
DRB5*01, DQB1*06:02,DQB1*03:01, 
DPB1*04:01
NSHL, 
unknown
IV-g 4B 2 × ABVD, 6 × 
BEACOPPe, IFRT
25 A*03:01,A*25:01, B*07:02,B*18:01, 
C*07:02,C*12:03, DRB1*15:01, DRB5*01:01, 
DQB1*06:02, DPB1*04:01,DPB1*145:01
NSHL, EBER 
negative.
III-a NA NA 33 NA NA
ABVD, adriamycin, bleomycin, vinblastine, dacarbazine; BEACOPP, bleomycin, etoposide, cyclophosphamide, 
adriamycin, vincristine, procarbazine, prednisolone; IFRT, involved-field radiotherapy, LMP1, latent membrane protein 1; 
EBV, Epstein–Barr virus; EBER, - Epstein–Barr virus-encoded small RNAs; NSHL, nodular sclerosis Hodgkin lymphoma; 
NA, not available.
Figure 1:  (A) SLC26A6 and (B) KLHDC8B expression in lymphoblastoid cells from patients and controls. Mean relative expression 
in lymphoblastoid cell lines derived from mutations carriers III-g, IV-f and IV-g (blue) and ten non-carriers (red). Cell lines assayed in 
triplicate and normalized against GAPDH expression. Values are mean of replicates and carrier status. Error bars denote 95% confidence 
intervals.*P < 0.05.
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candidates for cHL risk. In contrast, we did not identify 
any mutations in KLHDC8B, which has been previously 
suggested as a cause of familial cHL [19], and which 
lies within the linkage peak on 3p21 only ~500kb from 
SLC26A6. 
SLC26A6 is expressed in many tissues, consistent 
with its role as an anion transporter [22, 23]. SLC26A6 has 
so far not been directly implicated in cancer. FAM107A,
originally identified in a commonly deleted region on 3p21 
in renal cell carcinoma, appears to function as a tumour 
suppressor [24–26]. Loss of heterozygosity at 3p21 is 
common in human malignancies [24, 27–30], although 
the region has not been shown to be recurrently lost or 
gained in primary HRS cells [31, 32]. However, both 
Figure 2:  (A) SLC26A6 (B) FAM107A (C) KLHDC8B expression in established cell lines. Hodgkin lymphoma cell lines: KM-H2, L1236, 
HD-MyZ, L428, HDML-2. Each cell line was assayed in triplicate and normalized against GAPDH expression. Expression of FAM107A 
in L428, HDML-2, L540, HeLa and SU-DHL1 was below the limit of detection. Data are shown as mean (± standard error of the mean).
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cHL and non-Hodgkin lymphoma have been reported to 
display chromosomal rearrangements involving this region 
by fluorescent in situ hybridization [33]. Furthermore, 
the International Cancer Genome Consortium report 
that mutations in SLC26A6 and FAM107A occur in 3.7% 
(9/241) and 12.9% (31/241) respectively of germinal 
centre B-cell derived lymphomas [34]. Although we were 
able to demonstrate lower SLC26A6 mRNA expression 
in LCLs of affected individuals, we have been unable 
to provide a mechanistic basis by which identified 
variants in either SLC26A6 or FAM107A contributes to 
lymphomagenesis.
Although WES is a well-recognised strategy to 
identify disease-causing mutations [35, 36], it does not 
identify pathogenic non-coding abnormalities, which are 
increasingly recognised to be important [37, 38]. Hence, 
we cannot exclude the possibility that susceptibility to 
cHL in the family might be mediated through non-coding 
changes within the linked region. Reference to GWAS 
data has however provided evidence that common genetic 
variation does not underscore the linkage signal at 3p21. In 
addition, this study would be further enhanced by analysis 
of data relating to unaffected individuals in this family.
In summary, our analysis of this family support the 
existence of a susceptibility locus on chromosome 3p21 
for cHL, with exome sequencing suggesting SLC26A6 and 
FAM107A as possible candidate genes. 
MATERIALS AND METHODS
Hodgkin lymphoma family 
Collection of blood samples and clinical information 
from subjects was undertaken with informed consent and 
relevant ethical review board approval (North of Scotland 
regional ethics committee (12/NS/0105), in accordance 
with the tenets of the Declaration of Helsinki.
A family segregating cHL was identified through 
a female patient (IV-f) diagnosed with NSHL at age 22 
under the clinical care of the Department of Haematology 
at Aberdeen Royal Infirmary, UK (Figure 4). A detailed 
family history taken from this index case revealed that 
Figure 3: Immunohistochemistry of SLC26A6 and FAM107A in other tissues and Hodgkin lymphoma node biopsy. 
Photos (20×) of representative examples illustrating SLC26A6 staining of renal biopsy (A) and Hodgkin node (B); FAM107A staining of 
colorectal cancer tissue (C) and Hodgkin node (D). Immunostaining indicated by DAB, counterstained with haematoxylin.
Oncotarget20382www.oncotarget.com
three members of her extended family had also been 
diagnosed with NSHL (III-a; III-g, IV-b), all before age 
35 (Table 1). During the time the family has been under 
investigation, IV-g was diagnosed with stage 4B cHL 
at age 25. For four of the five affected family members 
(III-g, IV-f, IV-b, IV-g) the diagnosis of NSHL was 
confirmed by histological and immunohistochemical 
studies through reference to patient notes and diagnostic 
pathology. Tumors from IV-f and IV-g were EBV-negative 
(Table 1) by immunohistochemistry (LMP1) or in situ 
hybridization (EBER). In all family members, complete 
remission was attained with first-line standard treatment 
(i.e. chemotherapy ± radiotherapy). None had a significant 
medical history or past history of cancers and IV-f was 
found to have a normal constitutional chromosome 
karyotype. 
Genetic analysis of affected family members 
Constitutional DNA was extracted from EDTA-
venous blood or saliva samples using either QiaAMP 
DNA mini kits (Qiagen, UK) or prep-IT purification 
(DNAGenotek, Canada) kits and quantified by Quant-
IT Picogreen (Invitrogen, UK). Family members were 
genotyped using either Affymetrix 6.0 chips (III-g, IV-b, 
IV-f, IV-g) or Affymetrix 500K (III-a) mapping arrays. 
CEL intensity files were processed using Affymetrix 
Power Tools (APT v1.16.1) and PLINK used to harmonise 
genotypes. Mendelian errors were removed and SNPs 
with high heterozygosity spaced ~0.3Mb apart selected 
using linkdatagen were used for linkage analysis [39]. 
Non-parametric linkage analysis was performed using 
MERLIN [40]. 
Typing of classical HLA alleles was performed 
using SeCore sequencing (Life Technologies, UK) 
in conjunction with Applied Biosystems 3130XL 
technology and analysed using uTYPE 6.0 software (Life 
Technologies) with IMGT as reference (version 3.14.0). 
For WES of germline DNA from III-a, IV-b, IV-f and 
IV-g was fragmented using a Covaris E Series instrument 
(Covaris, United States). Indexed paired-end libraries 
were prepared using the SureSelect Human All Exon 
50Mb (Agilent, United States) and 2 × 100 bp sequencing 
performed using Illumina HiSeq2000 technology 
(Illumina, United States). Paired end fastq files were 
extracted using CASAVA software (v.1.8.1, Illumina) and 
aligned to build 37 (hg19) of the human reference genome 
using Stampy and BWA software [41, 42]. Alignments 
were processed using the Genome Analysis Tool Kit 
(GATK) pipeline [43]. We imposed GATK internal calling 
thresholds and required a genotyping quality (GQ) of ≥ 
30. Only non-silent variants were considered for analysis 
(i.e. missense, nonsense, frameshift, in-frame insertion/
deletions, splice donor/acceptors, and initiator codon 
variants). Exome Variant Server (NHLBI GO Exome 
Sequencing Project (ESP) [44], 1000 genomes project 
[45] and dbSNP [46] were used as population frequency 
references. Functional consequences of missense changes 
were predicted using SIFT [20] and POLYPHEN [21] 
algorithms. Sanger confirmation of sequence changes 
was carried out by using Big-Dye Ver 3.1 chemistry 
implemented on an ABI3730xl (Applied Biosystems, 
Foster City, USA).
Detailed studies of SLC26A6 and FAM107A
Immunohistochemistry of SLC26A6 and FAM107A 
were performed on formalin-fixed, paraffin-embedded 
material lymph node biopsies from IV-f and sporadic cHL 
(n = 5) patients using primary antibodies to SLC26A6 
Figure 4: Family segregating cHL: Circles, female and squares, male. Filled-in symbols represent individuals with nodular 
sclerosis Hodgkin lymphoma. Slash indicates individual is deceased. Arrow indicates proband.
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(Sigma) or FAM107A (Biorbyt) and DAB chromogen 
(Dako).
SLC26A6, KLHDC8B and FAM107A RNA 
expression was evaluated in lymphoblastoid cell lines 
(LCLs) derived from III-g, IV-f and IV-g and healthy 
controls (n = 10), HL cells (L428, L1236, HD-MyZ, KM-
H2, HDML-2) and other cell lines (L540, L591, A2780, 
HeLa, SU-DHL1). RNA was extracted using the RNeasy 
mini kit (Qiagen, UK) and qRT-PCR performed using 
a Roche LightCycler 480 thermal cycler. Assays were 
performed in triplicate with GAPDH as internal control.
Association at 2q35-37, 3p14-22, 21q22
To evaluate the association between common genetic 
variation at chromosomes 2q35-37, 3p14-22, 21q22 and 
cHL we made use of data previously generated on two 
non-overlapping case-control series of Northern European 
ancestry, which had been the subject of a previous GWAS 
[14]. The UK GWAS was based on 589 cases ascertained 
through Royal Marsden Hospitals National Health Service 
Trust Family History study during 2004–2008. Individuals 
from the 1958 Birth Cohort and National Blood Service 
served as controls [47]. The UK-NSHLG GWAS was based 
on 1,612 cases ascertained through the National Study of 
Hodgkin lymphoma Genetics [14]. Individuals from the 
BCAC and PRACTICAL consortia served as controls 
[48]. Collection of blood samples and clinical information 
from subjects was undertaken with informed consent and 
relevant ethical review board approval in accordance with 
the tenets of the Declaration of Helsinki. Full details of the 
genotyping and quality control are detailed in previously 
published work [14]. Briefly, we have previously confirmed 
an absence of systematic genetic differences between 
cases and controls and shown no significant evidence of 
population stratification in these sample sets. GWAS data 
were imputed to >10 million SNP with IMPUTE2 v2.392 
software [49], using a merged reference panel consisting 
of data from 1000 Genomes Project (phase 1 integrated 
release 3, March 2012) [45] and UK10K (ALSPAC, 
EGAS00001000090/EGAD00001000195 and TwinsUK 
EGAS00001000108/EGAS00001000194 studies) [50]. 
Tests of association between SNP genotype and cHL 
were performed under an additive genetic model in 
SNPTESTv2.5 [51]. Meta-analyses were performed under 
a fixed-effects model using META v1.6101 [52].
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